Form 8-K - Current report:
SEC Accession No. 0001178913-25-000143
Filing Date
2025-01-17
Accepted
2025-01-17 06:56:03
Documents
19
Period of Report
2025-01-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2532563.htm   iXBRL 8-K 65490
2 EXHIBIT 4.1 exhibit_4-1.htm EX-4.1 103830
3 EXHIBIT 4.2 exhibit_4-2.htm EX-4.2 99478
4 EXHIBIT 4.3 exhibit_4-3.htm EX-4.3 99008
5 EXHIBIT 10.1 exhibit_10-1.htm EX-10.1 202175
6 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 11307
  Complete submission text file 0001178913-25-000143.txt   908068

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA slxn-20250115.xsd EX-101.SCH 4741
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20250115_def.xml EX-101.DEF 18264
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20250115_lab.xml EX-101.LAB 27749
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20250115_pre.xml EX-101.PRE 20506
22 EXTRACTED XBRL INSTANCE DOCUMENT zk2532563_htm.xml XML 6552
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42253 | Film No.: 25536987
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)